Clinicopathological characteristics of triple-negative breast cancers

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 254-259

  Sasaki, Yuka ^a,b,c   Tsuda, Hitoshi ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Self Defense Forces Central Hospital   (Japan)

Author keywords

Basal like subtype; BRCA1; Histopathology; P53; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PACLITAXEL; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER SURVIVAL; CONFERENCE PAPER; DNA MICROARRAY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70349664011     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0153-5     Document Type: Conference Paper

References (39)

1. A Goldhirsch W Wood R Celber A Coats B Thurlimann HJ Senn 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
2. CM Perou T Sorlie MB Eisen M van de Rijn SS Jefferey CA Rees, et al. 2000 Molecular portraits of human breast tumors Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D (Pubitemid 30671230)
3. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
4. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
5. T Sorlie R Tibshirani J Parker T Hastit JS Marron A Nobel, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
6. S Umemura M Kurosumi T Moriya T Oyama K Arihiro H Yamashita, et al. 2006 Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol Breast Cancer 13 232 235 16929115 10.2325/jbcs.13.232
7. DC Allred JM Harvey M Berardo GM Clarl 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155 168 9504686 1:STN:280:DyaK1c7mtlaitg%3D%3D
8. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D
9. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote, et al. 2007 American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
10. JS Reis-Filho ANJ Tutt 2008 Triple negative tumors: a critical review Histopathology 52 108 118 18171422 10.1111/j.1365-2559.2008.03046.x 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D (Pubitemid 351724916)
11. S Chia B Norris C Speers M Cheang B Gilks AM Gown, et al. 2008 Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 5697 5704 19001334 10.1200/JCO.2007.15.8659 1:CAS:528:DC%2BD1MXotFemsw%3D%3D
12. DF Hayes AD Thor LG Dressler D Weaver S Edgerton D Cowan, et al. 2007 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496 1506 17928597 10.1056/NEJMoa071167 1:CAS:528:DC%2BD2sXhtFKmurrO (Pubitemid 47572635)
13. J Hugh J Hanson MC Cheang TO Nielsen CM Perou C Dumontet, et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 1168 1176 19204205 10.1200/JCO.2008.18.1024 1:CAS:528:DC%2BD1MXktFKhs7Y%3D
14. C Liedtke C Mazouni KR Hess F André A Tordai JA Mejia, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 18250347 10.1200/JCO.2007.14.4147
15. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Kouno T, et al. Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer. Proc Am Soc Clin Oncol. 2008;45(Part I):559
16. BP Schneider EP Winer WD Foulkes J Garber CM Perou A Richardson, et al. 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 8010 8018 19088017 10.1158/1078-0432.CCR-08-1208 1:CAS:528:DC%2BD1cXhsV2it73F
17. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 2568 2581 18487574 10.1200/JCO.2007.13.1748
18. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, et al., editors. World health organization classification of tumours. Pathology & genetics. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 13-59.
19. H Tsuda T Takarabe T Hasegawa T Murata S Hirohashi 1999 Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones Hum Pathol 30 1134 1139 10534158 10.1016/S0046-8177(99)90028-X 1:STN:280:DC%2BD3c%2FgtFOhtw%3D%3D (Pubitemid 29480879)
20. H Tsuda T Takarabe F Hasegawa T Fukutomi S Hirohashi 2000 Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases Am J Surg Pathol 24 197 202 10680887 10.1097/00000478-200002000-00005 1:STN:280:DC%2BD3c7ktlWhsA%3D%3D (Pubitemid 30078708)
21. The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 16th ed. Tokyo: Kanehara Shuppan; 2008.
22. M Smalley A Ashworth 2003 Stem cells and breast cancer: a field in transit Nat Rev Cancer 3 832 844 14668814 10.1038/nrc1212 1:CAS:528: DC%2BD3sXptFKlsL0%3D
23. BT Hennessy AM Gonzalez-Angulo K Stemke-Hale MZ Gilcrease S Krishnamurthy JS Lee, et al. 2009 Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics Cancer Res 69 4116 4124 19435916 10.1158/0008-5472.CAN-08-3441 1:CAS:528:DC%2BD1MXlvFWltrg%3D
24. CA Livasy G Karaca R Nanda MS Tretiakova OI Olopade DT Moore, et al. 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma Mod Pathol 19 264 271 16341146 10.1038/modpathol.3800528 1:CAS:528: DC%2BD28Xlt1eqtw%3D%3D (Pubitemid 43117611)
25. SM Rodriguez-Pinilla D Sarrio E Honrado G Moreno-Bueno D Hardisson F Calero, et al. 2007 Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J Clin Pathol 60 1006 1012 17105822 10.1136/jcp.2006.042143 (Pubitemid 47441933)
26. MJ Kim JY Ro SH Ahn HH Kim SB Kim G Gong 2006 Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER-2/neu-overexpressing phenotypes Hum Pathol 37 1217 1226 16938528 10.1016/j.humpath.2006.04.015 1:CAS:528:DC%2BD28XovVWrt7k%3D (Pubitemid 44286991)
27. M Laakso N Loman A Borg J Isola 2005 Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors Mod Pathol 18 1321 1328 15990899 10.1038/modpathol.3800456 1:CAS:528:DC%2BD2MXhtVWiu7fI (Pubitemid 41348650)
28. H Li P Cherukuri N Li V Cowling M Spinella M Cole, et al. 2007 Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors Cancer Res 67 501 510 17234757 10.1158/0008-5472.CAN-05-4571 1:CAS:528:DC%2BD2sXmtVKlsQ%3D%3D (Pubitemid 46192186)
29. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry, et al. 2006 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 5175 5180 10.1158/1078-0432.CCR-04-2424
30. K Savage MB Lambros D Robertson RL Jones C Jones A Mackay, et al. 2007 Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis Clin Cancer Res 13 90 101 17200343 10.1158/1078-0432.CCR-06-1371 1:CAS:528:DC%2BD2sXotlel (Pubitemid 46121857)
31. JS Reis-Filho D Steele S Di Palma RL Jones K Savage M James, et al. 2006 Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue Mod Pathol 19 307 319 16424897 10.1038/modpathol.3800542 1:CAS:528:DC%2BD28Xlt1equw%3D%3D (Pubitemid 43117617)
32. J Herschkowitz X He C Fan C Perou 2008 The functional loss of the retinoblastoma tumor suppressor is a common event in basal-like and luminal B breast cancers Breast Cancer Res 105 R75 10.1186/bcr2142
33. S Calza P Hall G Auer J Bjohle S Klaar U Kronenwett, et al. 2006 Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients Breast Cancer Res 8 R34 16846532 10.1186/bcr1517 (Pubitemid 44057559)
34. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele, et al. 2007 BRCA1 dysfunction in sporadic basal-like breast cancer Oncogene 26 2126 2132 17016441 10.1038/sj.onc.1210014 1:CAS:528:DC%2BD2sXjsFSiu7c%3D (Pubitemid 46514749)
35. J Garber A Richardson L Harris A Miron D Silver M Golshan, et al. 2006 Neoadjuvant cisplatin (CDDP) in triple-negative breast cancer (BC) Breast Cancer Res Treat 100 S149 10.1007/s10549-006-9235-7 Abstract 3074 (Pubitemid 44631916)
36. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-7.
37. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:189-91.
38. J Adelaide P Finetti I Bekhouche L Repellini J Geneiy F Sircoulomb, et al. 2007 Integrated profiling of basal and luminal breast cancers Cancer Res 67 11565 11575 18089785 10.1158/0008-5472.CAN-07-2536 1:CAS:528:DC%2BD2sXhsVCjs73F
39. K Chin S DeVries J Fridlyand PT Spellman R Roydasgupta WL Kuo, et al. 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 10 529 541 17157792 10.1016/j.ccr.2006.10.009 1:CAS:528:DC%2BD28XhtlCnsrbF (Pubitemid 44854748)